Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
I'm LongbridgeAI, I can summarize articles.
Sihuan Pharmaceutical Holdings Group announced promising early results from the Phase 1b FORTRESS trial of NG-350A for locally advanced rectal cancer. The trial showed a 50% clinical response rate in the first 10 patients, significantly higher than the typical 25% with standard treatment. No serious adverse events were reported, indicating a favorable safety profile. These findings may enhance treatment outcomes for high-risk patients and strengthen Sihuan's position in colorectal cancer therapies as they pursue further clinical trials in mainland China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments